Praxis Precision hits milestone in fight against rare paediatric seizures
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Subscribe To Our Newsletter & Stay Updated